{"nct_id": "NCT05261399", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Pemetrexed"}, {"drug_name": "Drug: Cisplatin"}, {"drug_name": "Drug: Savolitinib"}, {"drug_name": "Drug: Osimertinib"}, {"drug_name": "Drug: Carboplatin"}]}, "long_title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE3", "principal_investigator": "", "principal_investigator_institution": "AstraZeneca", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 324, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.", "* Participant must be \u226518 years (\u2265 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.", "* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.", "* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.", "* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.", "* Mandatory provision of FFPE tumour tissue.", "* MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.", "* Measurable disease as defined by RECIST 1.1.", "* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.", "* ECOG performance status of 0 or 1.", "Exclude - Exclusion Criteria:", "Exclude - * Predominant squamous NSCLC, and small cell lung cancer.", "Exclude - * Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.", "Exclude - * Prior or current treatment with savolitinib or another MET inhibitors.", "Exclude - * Spinal cord compression or brain metastases, unless asymptomatic and are stable.", "Exclude - * History or active leptomeningeal carcinomatosis.", "Exclude - * Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin \u2265 9.0 g/dL.", "Exclude - * Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals.", "Exclude - * History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.", "Exclude - * Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.", "Exclude - * Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.", "Exclude - * Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.", "Exclude - * Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2."], "short_title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "AstraZeneca", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.", "treatment_list": {"step": [{"arm": [{"arm_code": "Chemotherapy", "arm_internal_id": 0, "arm_description": "Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Pemetrexed", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Cisplatin", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Carboplatin", "level_internal_id": 2, "level_suspended": "N"}]}, {"arm_code": "Savolitinib + Osimertinib", "arm_internal_id": 1, "arm_description": "300 mg savolitinib BID plus 80 mg osimertinib QD", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Savolitinib", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Osimertinib", "level_internal_id": 1, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}